Metabolic Syndrome Prevalence in Renal Cell Cancer Patients

  • Bulut, Suleyman (Urology Clinic, Ankara Numune Education and Research Hospital) ;
  • Aktas, Binhan Kagan (Urology Clinic, Ankara Numune Education and Research Hospital) ;
  • Erkmen, Akif Ersoy (Urology Clinic, Ankara Numune Education and Research Hospital) ;
  • Ozden, Cuneyt (Urology Clinic, Ankara Numune Education and Research Hospital) ;
  • Gokkaya, Cevdet Serkan (Urology Clinic, Ankara Numune Education and Research Hospital) ;
  • Baykam, Mehmet Murat (Urology Clinic, Ankara Numune Education and Research Hospital) ;
  • Memis, Ali (Urology Clinic, Ankara Numune Education and Research Hospital)
  • 발행 : 2014.10.11


Purpose: Renal cell carcinoma (RCC) is increasingly being recognized as a metabolic disease in recent studies. The aim of the present study was to identify the prevalence of metabolic syndrome (MetS) and its association with RCC among urologic patients. Materials and Methods: The study included a total of 355 participants (117 adult RCC patients and 238 age matched controls) divided into groups, with and without MetS diagnosed using the criteria of the American Heart Association/The National Heart Lung and Blood Institute. Groups were compared statistically and logistic regression analysis was performed to investigate the impact of MetS criteria on RCC risk. Results: Of the 117 RCC patients, 52 (44.4%) and of the 238 controls, 37 (15.5%) had MetS. A significant association (p<0.001) was found between the presence of MetS and RCC (OR: 4.35; 95% CI=2.62-7.21). As the number of MetS components accumulated from 3 to 5, RCC risk increased likewise from 4 to 6 times. Conclusions: MetS is more prevalent in RCC patients in Turkey compared to controls. Risk increases with the number of coexisting MetS components.


  1. Azeem K, Kollarova H, Horakova D, Magnuskova S, Janout V (2011). Genetic syndromes associated with renal cell carcinoma: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 155, 231-8.
  2. Alberti KG, Zimmet P, Shaw J (2005). IDF Epidemiology task force consensus group. the metabolic syndrome-a new worldwide definition. Lancet, 366, 1059-62.
  3. Brock K, Gridley G, Lynch C, Ershow A, Cantor K (2007). Obesity and hypertension interact to increase risk of renal cell carcinoma in Iowa, USA. Obes Res Clin Pract, 1, 1-2.
  4. Faul F, Erdfelder E, Buchner A, Lang AG (2009). Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods, 41, 1149-60.
  5. Ferlay J, Shin HR, Bray F, et al (2008). Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer, 127, 2893-917.
  6. Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA, 287, 356-9.
  7. Forootan M, Tabatabaeefar M, Yahyaei M, Maghsoodi N (2012). Metabolic syndrome and colorectal cancer: a cross-sectional survey. Asian Pac J Cancer Prev, 13, 4999-5002.
  8. Haggstrom C, Rapp K, Stocks T, et al (2013). Metabolic factors associated with risk of renal cell carcinoma. PLoS One, 8, 57475.
  9. Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S (2013). Incidence of new-onset hypertension in cancer patients, a retrospective cohort study. Int J Hypertens, 2013, 379252.
  10. Grundy SM, Cleeman JI, Daniels SR, et al (2005). American heart association, national heart, lung, and blood institute. diagnosis and management of the metabolic syndrome, an American heart association/national heart, lung and blood institute scientific statement. Circulation, 112, 2735-52.
  11. Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM (2013). Association between C-reactive protein and risk of cancer: a metaanalysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8.
  12. Hammarsten J, Peeker R (2011). Urological aspects of the metabolic syndrome. Nat Rev Urol, 8, 483-94.
  13. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277-300.
  14. Jonasch E, Futreal PA, Davis IJ, et al (2012). State of the science, an update on renal cell carcinoma. Mol Cancer Res, 10, 859-80.
  15. Kaneko R, Sato Y, An Y, et al (2010). Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma. Asian Pac J Cancer Prev, 11, 975-83.
  16. Linehan WM, Ricketts CJ (2013). The metabolic basis of kidney cancer. Semin Cancer Biol, 23, 46-55.
  17. Morita T, Tabata S, Mineshita M, et al (2005). The metabolic syndrome is associated with increased risk of colorectal adenoma development, the self-defense forces health study. Asian Pac J Cancer Prev, 6, 485-9.
  18. Ozbek E, Otunctemur A, Dursun M, et al (2014). Association between the metabolic syndrome and high tumor grade and stage of primary urothelial cell carcinoma of the bladder. Asian Pac J Cancer Prev, 15, 1447-51.
  19. Navai N, Wood CG (2012). Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol, 30, 220-4.
  20. Otunctemur A, Ozbek E, Sahin S, et al (2014). Diabetes mellitus as a risk factor for high grade renal cell carcinoma. Asian Pac J Cancer Prev, 15, 3993-6.
  21. Ozbek E, Otunctemur A, Sahin S, et al (2013). Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome. Asian Pac J Cancer Prev, 14, 7351-4.
  22. Ozbek E, Otunctemur A, Dursun M, et al (2014). The metabolic syndrome is associated with more aggressive prostate cancer. Asian Pac J Cancer Prev, 15, 4029-32.
  23. Pothiwala P, Jain SK, Yaturu S (2009). Metabolic syndrome and cancer. Metab Syndr Relat Disord, 7, 279-88.
  24. Protzel C, Maruschke M, Hakenberg OW (2012). Epidemiology, aetiology and pathogenesis of renal cell carcinoma. Eur Urol Supp, 11, 52-9.
  25. Ronco AL, De Stefani E, Deneo-Pellegrini H, Quarneti A (2012). Diabetes, overweight and risk of postmenopausal breast cancer, a case-control study in Uruguay. Asian Pac J Cancer Prev, 13, 139-46.
  26. Ulaganathan V, Kandiah M, Zalilah MS, et al (2012). Colorectal cancer and its association with the metabolic syndrome, a Malaysian multi-centric case-control study. Asian Pac J Cancer Prev, 13, 3873-7.
  27. Van Hemelrijck M, Garmo H, Hammar N, et al (2012). The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int J Cancer, 130, 2118-28.
  28. Zhu Y, Wang HK, Zhang HL, et al (2013). Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma. J Urol, 189, 447-53.
  29. Weikert S, Boeing H, Pischon T, et al. (2008). Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol, 167, 438-46.
  30. Weikert S, Ljungberg B (2010). Contemporary epidemiology of renal cell carcinoma, perspectives of primary prevention. World J Urol, 28, 247-52.
  31. Wu Q, He XD, Yu L, Liu W, Tao LY (2012). The metabolic syndrome and risk factors for biliary tract cancer, a case-control study in China. Asian Pac J Cancer Prev, 13, 1963-9.

피인용 문헌

  1. Obesity and its implications on oncological urological surgery vol.27, pp.5, 2017,
  2. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer vol.35, pp.1, 2017,
  3. Prevention of kidney cancer incidence and recurrence pp.0963-0643, 2017,